Review



her2 lyophilized human her2 protein  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    R&D Systems her2 lyophilized human her2 protein
    Her2 Lyophilized Human Her2 Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 152 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/her2+lyophilized+human+her2+protein/Recombinant+Human+ErbB2%2FHer2+Fc+Chimera+Protein%2C+CF/us10556933-185-2-7
    Average 95 stars, based on 152 article reviews
    her2 lyophilized human her2 protein - by Bioz Stars, 2026-09
    95/100 stars

    Images

    Related Articles

    Concentration Assay:

    Article Title: Polypeptide libraries with a predetermined scaffold
    Article Snippet: .. Biotinylation of HER2 Lyophilized human HER2 protein (R&D Systems, #1129-ER) is dissolved in PBS (2.68 mM KCl, 1.47 mM KH2PO4, 137 mM NaCl, 8.1 mM Na2HPO4, pH 7.4) to a final concentration of 10 mg/ml. .. EZ-link Sulfo-NHS-LC-Biotin (Pierce, #21335) is dissolved in water to a final concentration of 1 mg/ml and a 5 and 30 fold molar excess is added to 500 μg HER2 in a total volume of 0.5 ml.

    Article Title: Polypeptide libraries with a predetermined scaffold
    Article Snippet: .. Biotinylation of HER2 Lyophilized human HER2 protein (R&D Systems, #1129-ER) is dissolved in PBS (2.68 mM KCl, 1.47 mM KH2PO4, 137 mM NaCl, 8.1 mM Na2HPO4, pH 7.4) to a final concentration of 10 mg/ml. .. EZ-link Sulfo-NHS-LC-Biotin (Pierce, #21335) is dissolved in water to a final concentration of 1 mg/ml and a 5 and 30 fold molar excess is added to 500 μg HER2 in a total volume of 0.5 ml.



    Similar Products

    her2 lyophilized human her2 protein  (R&D Systems)
    95
    R&D Systems her2 lyophilized human her2 protein
    Her2 Lyophilized Human Her2 Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/her2+lyophilized+human+her2+protein/Recombinant+Human+ErbB2%2FHer2+Fc+Chimera+Protein%2C+CF/us10556933-185-2-7
    Average 95 stars, based on 1 article reviews
    her2 lyophilized human her2 protein - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    her2 proteins  (Revvity)
    91
    Revvity her2 proteins
    Intrinsic and apparent binding affinity to target antigens.
    Her2 Proteins, supplied by Revvity, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/her2+lyophilized+human+her2+protein/ErbB2+%2F+HER2+(human)%2C+lyophilized/pmc05220356-170-31-40
    Average 91 stars, based on 1 article reviews
    her2 proteins - by Bioz Stars, 2026-09
    91/100 stars
    		  Buy from Supplier

    Image Search Results


    Intrinsic and apparent binding affinity to target antigens.

    Journal: Scientific Reports

    Article Title: Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence

    doi: 10.1038/srep40098

    Figure Lengend Snippet: Intrinsic and apparent binding affinity to target antigens.

    Article Snippet: After washing with FACS buffer, cell-bound DuetMab was detected by PE-conjugated goat anti-human Fcγ (Jackson ImmunoResearch) and free antigen binding arms on cell-bound DuetMab were detected by biotinylated soluble EGFR and HER2 proteins at 5 nM followed by Streptavidin-Allophycocyanin (APC) (Biolegend).

    Techniques: Binding Assay

    Doubling rate and receptor density properties of parental NCI-H358 and NCI-H358.HER2.ko tumor cell-lines.

    Journal: Scientific Reports

    Article Title: Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence

    doi: 10.1038/srep40098

    Figure Lengend Snippet: Doubling rate and receptor density properties of parental NCI-H358 and NCI-H358.HER2.ko tumor cell-lines.

    Article Snippet: After washing with FACS buffer, cell-bound DuetMab was detected by PE-conjugated goat anti-human Fcγ (Jackson ImmunoResearch) and free antigen binding arms on cell-bound DuetMab were detected by biotinylated soluble EGFR and HER2 proteins at 5 nM followed by Streptavidin-Allophycocyanin (APC) (Biolegend).

    Techniques:

    ( a ) Cell binding of anti-HER2 trastuzumab. ( b ) Cell binding of anti-EGFR GA201 IgG. ( c ) Cytotoxic activity of trastuzumab. ( d ) Cytotoxic activity of GA201 IgG. Each point represents the mean values of triplicate wells and the ± standard error of the mean (SEM) is represented by error bars.

    Journal: Scientific Reports

    Article Title: Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence

    doi: 10.1038/srep40098

    Figure Lengend Snippet: ( a ) Cell binding of anti-HER2 trastuzumab. ( b ) Cell binding of anti-EGFR GA201 IgG. ( c ) Cytotoxic activity of trastuzumab. ( d ) Cytotoxic activity of GA201 IgG. Each point represents the mean values of triplicate wells and the ± standard error of the mean (SEM) is represented by error bars.

    Article Snippet: After washing with FACS buffer, cell-bound DuetMab was detected by PE-conjugated goat anti-human Fcγ (Jackson ImmunoResearch) and free antigen binding arms on cell-bound DuetMab were detected by biotinylated soluble EGFR and HER2 proteins at 5 nM followed by Streptavidin-Allophycocyanin (APC) (Biolegend).

    Techniques: Binding Assay, Activity Assay

    ( a ) Concurrent binding analysis of anti-EGFR/HER2 DuetMab to parental NCI-H358 cells. ( b ) Concurrent binding analysis of anti-EGFR/HER2 DuetMab to NCI-H358.HER2.ko cells. To determine concurrent binding of EGFR and HER2 receptors by cell-bound DuetMab, each cell population was examined individually using fluorescent dye labeled EGFR and HER2 antigens. (Y-axis), Detection of cell-bound DuetMab. (X-axis), Detection of free antigen binding arms on cell-bound DuetMab. Data points refer to serial dilutions of the DuetMab starting at a sub-saturating concentration of 1.2 nM. Each point represents the mean values of duplicate wells and the ± standard error of the mean (SEM) is represented by error bars.

    Journal: Scientific Reports

    Article Title: Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence

    doi: 10.1038/srep40098

    Figure Lengend Snippet: ( a ) Concurrent binding analysis of anti-EGFR/HER2 DuetMab to parental NCI-H358 cells. ( b ) Concurrent binding analysis of anti-EGFR/HER2 DuetMab to NCI-H358.HER2.ko cells. To determine concurrent binding of EGFR and HER2 receptors by cell-bound DuetMab, each cell population was examined individually using fluorescent dye labeled EGFR and HER2 antigens. (Y-axis), Detection of cell-bound DuetMab. (X-axis), Detection of free antigen binding arms on cell-bound DuetMab. Data points refer to serial dilutions of the DuetMab starting at a sub-saturating concentration of 1.2 nM. Each point represents the mean values of duplicate wells and the ± standard error of the mean (SEM) is represented by error bars.

    Article Snippet: After washing with FACS buffer, cell-bound DuetMab was detected by PE-conjugated goat anti-human Fcγ (Jackson ImmunoResearch) and free antigen binding arms on cell-bound DuetMab were detected by biotinylated soluble EGFR and HER2 proteins at 5 nM followed by Streptavidin-Allophycocyanin (APC) (Biolegend).

    Techniques: Binding Assay, Labeling, Concentration Assay

    Cell cytotoxicity and calculated target selectivity parameter (TSP) values of anti-EGFR/HER2 bsAb variants.

    Journal: Scientific Reports

    Article Title: Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence

    doi: 10.1038/srep40098

    Figure Lengend Snippet: Cell cytotoxicity and calculated target selectivity parameter (TSP) values of anti-EGFR/HER2 bsAb variants.

    Article Snippet: After washing with FACS buffer, cell-bound DuetMab was detected by PE-conjugated goat anti-human Fcγ (Jackson ImmunoResearch) and free antigen binding arms on cell-bound DuetMab were detected by biotinylated soluble EGFR and HER2 proteins at 5 nM followed by Streptavidin-Allophycocyanin (APC) (Biolegend).

    Techniques:

    ( a ) Selective cytotoxic activity of parental EGFR/HER2 DuetMab. ( b ) Selective cytotoxic activity of VκF94A/HER2 DuetMab variant. ( c ) Selective cytotoxic activity of VκS93A + V H P97A/HER2 DuetMab variant. ( d ) Selective cytotoxic activity of VκF94A + V H P97A/HER2 DuetMab variant. ( e ) Selective cytotoxic activity of VκS93A + V H P97A/HER2 IgG-scFv variant. ( f ) Selective cytotoxic activity of VκF94A + V H P97A/HER2 IgG-scFv variant. ( g ) Mean of TSP values based upon data from three independent experiments. To determine selective cell targeting and elimination, the double-positive NCI-H358 cells and single-positive NCI-H358.HER2.ko cells were pre-stained with different tracer dyes, combined at equal ratios and incubated with serial dilutions of the various bsAbs. Selective cytotoxic activity was determined by cell imaging cytometry. Each point on the graphs represents the mean values of triplicate wells and the ± standard error of the mean (SEM) is represented by error bars. Statistical significance was determined by One way ANOVA for multiple comparisons (P < 0.05 *P < 0.01 **P < 0.001 ***P < 0.0001 ****ns: not significant).

    Journal: Scientific Reports

    Article Title: Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence

    doi: 10.1038/srep40098

    Figure Lengend Snippet: ( a ) Selective cytotoxic activity of parental EGFR/HER2 DuetMab. ( b ) Selective cytotoxic activity of VκF94A/HER2 DuetMab variant. ( c ) Selective cytotoxic activity of VκS93A + V H P97A/HER2 DuetMab variant. ( d ) Selective cytotoxic activity of VκF94A + V H P97A/HER2 DuetMab variant. ( e ) Selective cytotoxic activity of VκS93A + V H P97A/HER2 IgG-scFv variant. ( f ) Selective cytotoxic activity of VκF94A + V H P97A/HER2 IgG-scFv variant. ( g ) Mean of TSP values based upon data from three independent experiments. To determine selective cell targeting and elimination, the double-positive NCI-H358 cells and single-positive NCI-H358.HER2.ko cells were pre-stained with different tracer dyes, combined at equal ratios and incubated with serial dilutions of the various bsAbs. Selective cytotoxic activity was determined by cell imaging cytometry. Each point on the graphs represents the mean values of triplicate wells and the ± standard error of the mean (SEM) is represented by error bars. Statistical significance was determined by One way ANOVA for multiple comparisons (P < 0.05 *P < 0.01 **P < 0.001 ***P < 0.0001 ****ns: not significant).

    Article Snippet: After washing with FACS buffer, cell-bound DuetMab was detected by PE-conjugated goat anti-human Fcγ (Jackson ImmunoResearch) and free antigen binding arms on cell-bound DuetMab were detected by biotinylated soluble EGFR and HER2 proteins at 5 nM followed by Streptavidin-Allophycocyanin (APC) (Biolegend).

    Techniques: Activity Assay, Variant Assay, Staining, Incubation, Imaging, Cytometry

    ( a ) Selective tumor-targeting activity of parental EGFR/HER2 DuetMab. ( b ) Selective tumor-targeting activity of VκF94A/HER2 DuetMab variant. ( c ) Selective tumor-targeting activity of VκS93A + V H P97A/HER2 DuetMab variant. ( d ) Selective tumor-targeting activity of VκF94A + V H P97A/HER2 DuetMab variant. ( e ) Selective tumor-targeting activity of VκS93A + V H P97A/HER2 IgG-scFv variant. ( f ) Selective tumor-targeting activity of VκF94A + V H P97A/HER2 IgG-scFv variant. To determine tumor-targeting selectivity, the double-positive NCI-H358 cells as “target tumor” and single-positive NCI-H358.HER2.ko cells as “normal tissue” were grafted on opposing flanks of athymic nude mice. Dual-flank tumor bearing mice were treated twice weekly with the various bsAbs for a total of 8 treatments and selective tumor growth inhibition was measured twice weekly. Tumor size represents the mean values of 8 mice per treatment group and the ± standard error of the mean (SEM) is represented by error bars. Statistical comparisons were conducted by calculating the area under the curve (AUC) of paired “target” and “non-target” tumors, and significance of tumor selectivity was determined by paired t-test (P < 0.05 *P < 0.01 **P < 0.001 ***P < 0.0001 ****ns: not significant).

    Journal: Scientific Reports

    Article Title: Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence

    doi: 10.1038/srep40098

    Figure Lengend Snippet: ( a ) Selective tumor-targeting activity of parental EGFR/HER2 DuetMab. ( b ) Selective tumor-targeting activity of VκF94A/HER2 DuetMab variant. ( c ) Selective tumor-targeting activity of VκS93A + V H P97A/HER2 DuetMab variant. ( d ) Selective tumor-targeting activity of VκF94A + V H P97A/HER2 DuetMab variant. ( e ) Selective tumor-targeting activity of VκS93A + V H P97A/HER2 IgG-scFv variant. ( f ) Selective tumor-targeting activity of VκF94A + V H P97A/HER2 IgG-scFv variant. To determine tumor-targeting selectivity, the double-positive NCI-H358 cells as “target tumor” and single-positive NCI-H358.HER2.ko cells as “normal tissue” were grafted on opposing flanks of athymic nude mice. Dual-flank tumor bearing mice were treated twice weekly with the various bsAbs for a total of 8 treatments and selective tumor growth inhibition was measured twice weekly. Tumor size represents the mean values of 8 mice per treatment group and the ± standard error of the mean (SEM) is represented by error bars. Statistical comparisons were conducted by calculating the area under the curve (AUC) of paired “target” and “non-target” tumors, and significance of tumor selectivity was determined by paired t-test (P < 0.05 *P < 0.01 **P < 0.001 ***P < 0.0001 ****ns: not significant).

    Article Snippet: After washing with FACS buffer, cell-bound DuetMab was detected by PE-conjugated goat anti-human Fcγ (Jackson ImmunoResearch) and free antigen binding arms on cell-bound DuetMab were detected by biotinylated soluble EGFR and HER2 proteins at 5 nM followed by Streptavidin-Allophycocyanin (APC) (Biolegend).

    Techniques: Activity Assay, Variant Assay, Inhibition

    ( a ) Antitumor activity of parental GA201 formatted as either bispecific anti-EGFR/HER2 DuetMab or monospecific anti-EGFR/NMGC DuetMab. ( b ) Antitumor activity of variant VκF94A formatted as either bispecific anti-EGFR/HER2 DuetMab or monospecific anti-EGFR/NMGC DuetMab. ( c ) Antitumor activity of variant VκS93A + V H P97A formatted as either bispecific anti-EGFR/HER2 DuetMab or monospecific anti-EGFR/NMGC DuetMab. ( d ) Antitumor activity of variant VκF94A + V H P97A formatted as either bispecific anti-EGFR/HER2 DuetMab or monospecific anti-EGFR/NMGC DuetMab. Single-flank tumor bearing mice were treated twice weekly with monospecific and bispecific formats of the EGFR affinity-modulated variants for a total of 8 treatments and tumor growth inhibition was measured twice weekly. Tumor size represents the mean values of 5 mice per treatment group and the ± standard error of the mean (SEM) is represented by error bars. Statistical comparisons were conducted by calculating the area under the curve (AUC) comparing each monospecific DuetMab with its corresponding bispecific DuetMab. Statistical significance was determined by unpaired t-test (P < 0.05 *P < 0.01 **P < 0.001 ***P < 0.0001 ****ns: not significant).

    Journal: Scientific Reports

    Article Title: Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence

    doi: 10.1038/srep40098

    Figure Lengend Snippet: ( a ) Antitumor activity of parental GA201 formatted as either bispecific anti-EGFR/HER2 DuetMab or monospecific anti-EGFR/NMGC DuetMab. ( b ) Antitumor activity of variant VκF94A formatted as either bispecific anti-EGFR/HER2 DuetMab or monospecific anti-EGFR/NMGC DuetMab. ( c ) Antitumor activity of variant VκS93A + V H P97A formatted as either bispecific anti-EGFR/HER2 DuetMab or monospecific anti-EGFR/NMGC DuetMab. ( d ) Antitumor activity of variant VκF94A + V H P97A formatted as either bispecific anti-EGFR/HER2 DuetMab or monospecific anti-EGFR/NMGC DuetMab. Single-flank tumor bearing mice were treated twice weekly with monospecific and bispecific formats of the EGFR affinity-modulated variants for a total of 8 treatments and tumor growth inhibition was measured twice weekly. Tumor size represents the mean values of 5 mice per treatment group and the ± standard error of the mean (SEM) is represented by error bars. Statistical comparisons were conducted by calculating the area under the curve (AUC) comparing each monospecific DuetMab with its corresponding bispecific DuetMab. Statistical significance was determined by unpaired t-test (P < 0.05 *P < 0.01 **P < 0.001 ***P < 0.0001 ****ns: not significant).

    Article Snippet: After washing with FACS buffer, cell-bound DuetMab was detected by PE-conjugated goat anti-human Fcγ (Jackson ImmunoResearch) and free antigen binding arms on cell-bound DuetMab were detected by biotinylated soluble EGFR and HER2 proteins at 5 nM followed by Streptavidin-Allophycocyanin (APC) (Biolegend).

    Techniques: Activity Assay, Variant Assay, Inhibition